Processa Pharmaceuticals, Inc. (PCSA)
| Market Cap | 5.12M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.11M |
| Shares Out | 2.75M |
| EPS (ttm) | -7.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,382 |
| Open | 2.030 |
| Previous Close | 1.890 |
| Day's Range | 1.860 - 2.030 |
| 52-Week Range | 1.760 - 14.243 |
| Beta | 0.96 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About PCSA
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metasta... [Read more]
Financial Performance
Financial StatementsNews
Processa Pharmaceuticals Proxy statement: Proxy filing
Processa Pharmaceuticals filed a proxy statement on June 18, 2026, providing details for shareholder voting and corporate governance matters.
Processa Pharmaceuticals Quarterly report: Q1 2026
Processa Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Processa Pharmaceuticals Annual report: Q4 2025
Processa Pharmaceuticals has published its Q4 2025 annual report on March 18, 2026.
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today a...
Processa Pharmaceuticals completes enrollment of 20th patient in Phase 2 study
Processa Pharmaceuticals (PCSA) reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim analysis in its ongoing Phase 2 clinical study evaluatin...
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company deve...
Here’s Why Penny Stock Processa Pharmaceuticals (PCSA) Is Exploding Today
Penny stock Processa Pharmaceuticals ($PCSA) surged as much as 130% on Wednesday. The upside is due to encouraging preliminary data from its ongoing Phase 2 study evaluating next-generation cancer the...
Processa Pharmaceuticals provides update on Phase 2 NGS-Cap
Processa Pharmaceuticals (PCSA) provided a clinical update on its ongoing Phase 2 study of NGC-Cap, the combination treatment of PCS6422 and capecitabine, in patients with advanced or metastatic breas...
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine
Processa Pharmaceuticals Inc trading halted, news pending
19:50 EST Processa Pharmaceuticals (PCSA) Inc trading halted, news pending
Processa Pharmaceuticals Quarterly report: Q3 2025
Processa Pharmaceuticals has published its Q3 2025 quarterly earnings report on November 6, 2025.
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and inno...
Processa Pharmaceuticals price target lowered to $1 from $2 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Processa Pharmaceuticals (PCSA) to $1 from $2 and keeps a Buy rating on the shares. The firm cites equity…
Processa Pharmaceuticals Proxy statement: Proxy Filing
Processa Pharmaceuticals filed a proxy statement on August 25, 2025, providing details for shareholder voting and corporate governance matters.
Processa Pharmaceuticals Proxy statement: Proxy Filing
Processa Pharmaceuticals filed a proxy statement on August 13, 2025, providing details for shareholder voting and corporate governance matters.
Processa Pharmaceuticals Proxy statement: Proxy Filing
Processa Pharmaceuticals filed a proxy statement on August 8, 2025, providing details for shareholder voting and corporate governance matters.
Processa secures strategic investment, evaluates crypto strategy
Processa Pharmaceuticals (PCSA) announced that it has secured a strategic investment and that it is evaluating corporate cryptocurrency treasury strategies as part of its broader financial and growth ...
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
VERO BEACH, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for canc...
Processa Pharmaceuticals Quarterly report: Q2 2025
Processa Pharmaceuticals has published its Q2 2025 quarterly earnings report on August 7, 2025.
Processa Pharmaceuticals Proxy statement: Proxy Filing
Processa Pharmaceuticals filed a proxy statement on July 31, 2025, providing details for shareholder voting and corporate governance matters.
Processa Pharmaceuticals Transcript: Status Update
A de-risk approach focuses on improving existing cancer drugs, with a robust pipeline including PCS6422 and PCS11T showing strong efficacy and safety data. Strategic partnerships and regulatory expertise drive progress, with key catalysts expected in the second half of the year.
Processa terminates license agreement for PCS3117
Processa Pharmaceuticals (PCSA) provides updates on its product pipeline, upcoming milestones and business activities. Key Portfolio Updates: PCS6422: PCS6422, Processa’s lead oncology asset in combin...
Processa Pharmaceuticals Provides Portfolio and Business Update
Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852 Continue enrolling patients in Phase 2 study of PCS6422 Strengthened balance sheet with $7M capital infus...
Processa Pharmaceuticals price target lowered to $2 from $6 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Processa Pharmaceuticals (PCSA) to $2 from $6 and keeps a Buy rating on the shares after the company recently announced that it…
Processa sells 28M shares at 25c in public offering
Processa Pharmaceuticals (PCSA) announced the pricing of a public offering of 28M shares of common stock at a public offering price of 25c per share. The closing of the offering…